A detailed history of Two Sigma Investments, LP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Two Sigma Investments, LP holds 4,721,241 shares of BMY stock, worth $273 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
4,721,241
Previous 6,174,860 23.54%
Holding current value
$273 Million
Previous $256 Million 4.73%
% of portfolio
0.58%
Previous 0.62%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $57.7 Million - $75.2 Million
-1,453,619 Reduced 23.54%
4,721,241 $244 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $63.5 Million - $83.6 Million
1,577,529 Added 34.31%
6,174,860 $256 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $14.4 Million - $16.3 Million
-300,325 Reduced 6.13%
4,597,331 $249 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $40.5 Million - $48.3 Million
835,524 Added 20.57%
4,897,656 $251 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $50 Million - $56 Million
864,371 Added 27.03%
4,062,132 $236 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $86.2 Million - $95.7 Million
1,352,338 Added 73.28%
3,197,761 $204 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $63.5 Million - $72 Million
965,651 Added 109.76%
1,845,423 $128 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $35.1 Million - $41.6 Million
512,671 Added 139.65%
879,772 $63.3 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $327,991 - $194 Million
-2,523,011 Reduced 87.3%
367,101 $26.1 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $2.73 Million - $3 Million
-37,541 Reduced 1.28%
2,890,112 $223 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $58.5 Million - $70.2 Million
-952,148 Reduced 24.54%
2,927,653 $214 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $9.35 Million - $10.9 Million
174,412 Added 4.71%
3,879,801 $242 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $2.05 Million - $2.4 Million
34,680 Added 0.94%
3,705,389 $219 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $191 Million - $208 Million
3,078,135 Added 519.45%
3,670,709 $245 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $31.6 Million - $35.6 Million
533,016 Added 894.95%
592,574 $37.4 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $53.1 Million - $60.2 Million
-920,457 Reduced 93.92%
59,558 $3.69 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $16.3 Million - $18.1 Million
283,829 Added 40.77%
980,015 $59.1 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $33.3 Million - $38.9 Million
606,600 Added 677.11%
696,186 $40.9 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $55.8 Million - $81.2 Million
-1,203,503 Reduced 93.07%
89,586 $4.99 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $32.2 Million - $42 Million
-653,984 Reduced 33.59%
1,293,089 $83 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $36.2 Million - $42.9 Million
-846,469 Reduced 30.3%
1,947,073 $98.7 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $48.7 Million - $53.8 Million
-1,091,042 Reduced 28.09%
2,793,542 $127 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $149 Million - $177 Million
3,291,232 Added 554.68%
3,884,584 $185 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $6.37 Million - $8.26 Million
130,669 Added 28.24%
593,352 $30.8 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $42.3 Million - $47.7 Million
-765,613 Reduced 62.33%
462,683 $28.7 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $16.4 Million - $18.9 Million
273,423 Added 28.63%
1,228,296 $77.7 Million
Q4 2017

Feb 14, 2018

SELL
$59.94 - $65.35 $45.4 Million - $49.6 Million
-758,234 Reduced 44.26%
954,873 $58.5 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $94.6 Million - $109 Million
1,713,107
1,713,107 $109 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.